AAM Tells Commerce Department What FDA Regs It Wants Removed, Finalized

The generic drug lobby recently answered calls from the Trump administration to highlight regulations that negatively impact domestic manufacturing by telling the Commerce Department it wants FDA to withdraw its proposed generic drug labeling rule and quality metrics data guidance, and to revamp a biosimilar “deemed to be a license” guide. But the Association for Accessible Medicines isn't only calling for rules to be quashed: The lobby group says FDA should finalize a rule on electronic distribution of prescribing information...